IL222728A0 - Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites - Google Patents
Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activitesInfo
- Publication number
- IL222728A0 IL222728A0 IL222728A IL22272812A IL222728A0 IL 222728 A0 IL222728 A0 IL 222728A0 IL 222728 A IL222728 A IL 222728A IL 22272812 A IL22272812 A IL 22272812A IL 222728 A0 IL222728 A0 IL 222728A0
- Authority
- IL
- Israel
- Prior art keywords
- activites
- proliferative
- cancer
- analogs exhibiting
- dicarboxamides
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32954810P | 2010-04-29 | 2010-04-29 | |
| PCT/US2011/034556 WO2011137342A1 (en) | 2010-04-29 | 2011-04-29 | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL222728A0 true IL222728A0 (en) | 2012-12-31 |
Family
ID=44260801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL222728A IL222728A0 (en) | 2010-04-29 | 2012-10-28 | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20120058985A1 (enExample) |
| EP (1) | EP2563362B1 (enExample) |
| JP (1) | JP5795630B2 (enExample) |
| KR (1) | KR20130109943A (enExample) |
| CN (1) | CN103068384B (enExample) |
| AU (1) | AU2011245248B2 (enExample) |
| BR (1) | BR112012027743A2 (enExample) |
| CA (1) | CA2800569A1 (enExample) |
| DK (1) | DK2563362T3 (enExample) |
| ES (1) | ES2475741T3 (enExample) |
| IL (1) | IL222728A0 (enExample) |
| MX (1) | MX2012012571A (enExample) |
| PH (1) | PH12012502142A1 (enExample) |
| PT (1) | PT2563362E (enExample) |
| RU (1) | RU2012151012A (enExample) |
| SG (2) | SG10201503394PA (enExample) |
| WO (1) | WO2011137342A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2365752B1 (en) * | 2008-10-29 | 2014-09-24 | Deciphera Pharmaceuticals, Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| PH12012502142A1 (en) * | 2010-04-29 | 2017-04-21 | Deciphera Pharmaceuticals Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities |
| CN102702121B (zh) * | 2012-04-06 | 2016-04-13 | 浙江工业大学 | 一种化合物间羟基苯基四嗪二甲酰胺及制备和应用 |
| CN102702120A (zh) * | 2012-04-06 | 2012-10-03 | 浙江工业大学 | 一种新化合物邻羟基苯基四嗪二甲酰胺及制备和应用 |
| AU2013259583A1 (en) | 2012-05-08 | 2014-11-13 | The Regents Of The University Of California | Alpha 7 nicotinic acetylcholine allosteric modulators, their derivatives and uses thereof |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| ES2798899T3 (es) | 2013-02-25 | 2020-12-14 | Novartis Ag | Mutación novedosa del receptor de andrógenos |
| WO2014145023A1 (en) * | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2016061231A1 (en) * | 2014-10-14 | 2016-04-21 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
| EP3206752A1 (en) * | 2014-10-14 | 2017-08-23 | Deciphera Pharmaceuticals, LLC | Inhibition of trk kinase mediated tumor growth and disease progression |
| US20170079966A1 (en) * | 2014-10-14 | 2017-03-23 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
| BR112018068681A2 (pt) | 2016-03-16 | 2019-01-15 | Bayer Cropscience Ag | derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas |
| CN106349158B (zh) * | 2016-08-03 | 2020-02-28 | 杭州市西溪医院 | 一种c-Met小分子抑制剂、含其的药物组合物及其药学应用 |
| CN107793363B (zh) * | 2016-09-06 | 2021-02-26 | 上海医药工业研究院 | 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用 |
| CN106831707B (zh) * | 2016-12-28 | 2019-09-20 | 杭州市西溪医院 | 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途 |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| CN109988108B (zh) * | 2017-12-29 | 2022-04-29 | 江苏豪森药业集团有限公司 | 一种卡博替尼的制备方法 |
| AU2019215081B2 (en) | 2018-01-31 | 2024-07-25 | Deciphera Pharmaceuticals, Llc. | Combination therapy for the treatment of gastrointestinal stromal tumors |
| CN111886006B (zh) | 2018-01-31 | 2024-07-09 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| PT3902547T (pt) | 2018-12-28 | 2023-12-04 | Deciphera Pharmaceuticals Llc | Inibidores de csf1r para utilização no tratamento do cancro |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| SI3966206T1 (sl) | 2019-05-10 | 2023-12-29 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidinski amidni zaviralci avtofagije in načini njihove uporabe |
| HRP20231730T1 (hr) | 2019-05-10 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| CA3143489A1 (en) | 2019-06-17 | 2020-12-24 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| CN119970649A (zh) | 2019-12-30 | 2025-05-13 | 德西费拉制药有限责任公司 | 非晶型激酶抑制剂制剂及其使用方法 |
| FI4084779T3 (fi) | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia |
| WO2022109001A1 (en) | 2020-11-18 | 2022-05-27 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| EP4444429A1 (en) | 2021-12-09 | 2024-10-16 | Deciphera Pharmaceuticals, LLC | Raf kinase inhibitors and methods of use thereof |
| CN114394940B (zh) * | 2022-01-26 | 2024-01-16 | 武汉工程大学 | 一种环丙基-1,1二酰胺类化合物及其制备方法和应用 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| WO2025122952A1 (en) | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| WO2025231106A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070270421A1 (en) * | 2004-02-27 | 2007-11-22 | Tomohiro Matsushima | Novel pyridine Derivative and Pyrimidine Derivative (1) |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| DK1889836T3 (da) * | 2005-08-24 | 2013-08-19 | Eisai R&D Man Co Ltd | Hidtil ukendt pyridinderivat og pyrimidinderivat |
| US8003662B2 (en) | 2006-01-30 | 2011-08-23 | Array Biopharma, Inc. | Heterobicyclic thiophene compounds and methods of use |
| CA2661333C (en) | 2006-08-23 | 2014-08-05 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
| KR20090090365A (ko) | 2007-02-23 | 2009-08-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Ｈｇｆｒ 유전자 증폭 세포주에 대하여 우수한 세포 증식 억제 효과 및 항종양 효과를 나타내는 피리딘 유도체 또는 피리미딘 유도체 |
| WO2009033084A1 (en) | 2007-09-06 | 2009-03-12 | Array Biopharma Inc. | Pyrazolo-pyridines as tyrosine kinase inhibitors |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| US20090227556A1 (en) * | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| JPWO2009104520A1 (ja) | 2008-02-18 | 2011-06-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の製造方法（２） |
| TW201035017A (en) * | 2008-09-26 | 2010-10-01 | Smithkline Beecham Corp | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide |
| EP2365752B1 (en) * | 2008-10-29 | 2014-09-24 | Deciphera Pharmaceuticals, Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2010064300A1 (ja) | 2008-12-02 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 食道癌治療用組成物 |
| JP2010178651A (ja) | 2009-02-04 | 2010-08-19 | Eisai R & D Management Co Ltd | Ｈｇｆｒ阻害物質の作用検定方法 |
| PH12012502142A1 (en) * | 2010-04-29 | 2017-04-21 | Deciphera Pharmaceuticals Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities |
-
2011
- 2011-04-29 PH PH1/2012/502142A patent/PH12012502142A1/en unknown
- 2011-04-29 CN CN201180031486.XA patent/CN103068384B/zh not_active Expired - Fee Related
- 2011-04-29 BR BR112012027743A patent/BR112012027743A2/pt active Search and Examination
- 2011-04-29 RU RU2012151012/04A patent/RU2012151012A/ru not_active Application Discontinuation
- 2011-04-29 PT PT117194217T patent/PT2563362E/pt unknown
- 2011-04-29 WO PCT/US2011/034556 patent/WO2011137342A1/en not_active Ceased
- 2011-04-29 CA CA2800569A patent/CA2800569A1/en not_active Abandoned
- 2011-04-29 MX MX2012012571A patent/MX2012012571A/es active IP Right Grant
- 2011-04-29 ES ES11719421.7T patent/ES2475741T3/es active Active
- 2011-04-29 AU AU2011245248A patent/AU2011245248B2/en not_active Ceased
- 2011-04-29 JP JP2013508280A patent/JP5795630B2/ja not_active Expired - Fee Related
- 2011-04-29 SG SG10201503394PA patent/SG10201503394PA/en unknown
- 2011-04-29 EP EP11719421.7A patent/EP2563362B1/en not_active Not-in-force
- 2011-04-29 SG SG2012079760A patent/SG185073A1/en unknown
- 2011-04-29 US US13/098,243 patent/US20120058985A1/en not_active Abandoned
- 2011-04-29 DK DK11719421.7T patent/DK2563362T3/da active
- 2011-04-29 KR KR1020127031316A patent/KR20130109943A/ko not_active Ceased
-
2012
- 2012-05-24 US US13/480,108 patent/US20120252849A1/en not_active Abandoned
- 2012-07-26 US US13/559,170 patent/US8637672B2/en not_active Expired - Fee Related
- 2012-10-28 IL IL222728A patent/IL222728A0/en unknown
-
2013
- 2013-12-20 US US14/136,295 patent/US20140194405A1/en not_active Abandoned
-
2015
- 2015-01-22 US US14/602,781 patent/US20150218130A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8637672B2 (en) | 2014-01-28 |
| SG10201503394PA (en) | 2015-06-29 |
| JP2013525458A (ja) | 2013-06-20 |
| RU2012151012A (ru) | 2014-06-10 |
| EP2563362A1 (en) | 2013-03-06 |
| MX2012012571A (es) | 2013-04-05 |
| US20140194405A1 (en) | 2014-07-10 |
| SG185073A1 (en) | 2012-12-28 |
| ES2475741T3 (es) | 2014-07-11 |
| AU2011245248B2 (en) | 2016-01-07 |
| US20150218130A1 (en) | 2015-08-06 |
| CA2800569A1 (en) | 2011-11-03 |
| BR112012027743A2 (pt) | 2017-03-14 |
| WO2011137342A1 (en) | 2011-11-03 |
| CN103068384A (zh) | 2013-04-24 |
| US20120322834A1 (en) | 2012-12-20 |
| JP5795630B2 (ja) | 2015-10-14 |
| AU2011245248A1 (en) | 2012-12-20 |
| HK1184392A1 (zh) | 2014-01-24 |
| DK2563362T3 (da) | 2014-06-23 |
| US20120252849A1 (en) | 2012-10-04 |
| KR20130109943A (ko) | 2013-10-08 |
| PH12012502142A1 (en) | 2017-04-21 |
| US20120058985A1 (en) | 2012-03-08 |
| PT2563362E (pt) | 2014-07-11 |
| CN103068384B (zh) | 2015-03-11 |
| EP2563362B1 (en) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL222728A0 (en) | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites | |
| IL289629A (en) | 2-aminopyrimidine-6-one compounds and analogs showing anti-cancer and anti-proliferative activity | |
| GB2507535B (en) | Multilayer electrode | |
| IL233051B (en) | Anti-phf-tau antibodies and uses thereof | |
| IL232647A0 (en) | Pyridone amides and analogs exhibiting anticancer and antiproliferative activities | |
| ZA201501928B (en) | Pharmaceutical antiretroviral composition | |
| PL2569154T3 (pl) | Wielowarstwowy element kształtowy z drewna fornirowego | |
| GB201121453D0 (en) | Multilayer substraite | |
| GB2508097B (en) | Multi-layer slide member | |
| IL229243B (en) | Complementary factor b analogs and their uses | |
| PL2768485T3 (pl) | Nanozawiesina farmaceutyczna | |
| GB201111775D0 (en) | Compounds and uses thereof | |
| PL2632916T3 (pl) | Nowe środki przeciwnowotworowe | |
| EP2691106A4 (en) | ANTIVIRAL COMPOSITION | |
| EP2689675A4 (en) | SOSSENZUSAMMENSETZUNG | |
| SG10201509311WA (en) | Multilayer structure | |
| GB201121845D0 (en) | Pressurization device | |
| ZA201306909B (en) | Antiviral composition | |
| GB201112721D0 (en) | Antimalarial | |
| GB201110598D0 (en) | Pharmaceutical compositions and devices | |
| RS20100529A3 (en) | EASY READY TRIANGLE | |
| AU346934S (en) | Jumpsuit | |
| AU346091S (en) | Jumpsuit | |
| GB201015784D0 (en) | Anti-cancer compounds | |
| GB201303786D0 (en) | Multi use watercraft 2 |